Regencell Bioscience Holdings Ltd annual report, Q4 FY2026

Regencell Bioscience Holdings Limited — FY2026 Form 20-F

Reporting period: Fiscal year ended June 30, 2026; U.S. GAAP. The company is a Hong Kong-based, early-stage TCM bioscience developer focused on ADHD and autism spectrum disorder (ASD). It has no approved products and has generated no product revenue.

Financial performance and position

Metric	FY2026	FY2025
Revenue	$0	$0
Operating expenses	$11.72 million	$3.77 million
Net loss	$11.70 million	$3.58 million
Loss per share	$0.0237	$0.0072
Operating cash flow	$(7.70) million	$(3.11) million
Cash at year-end	$14.19 million	$2.42 million

• FY2026 general and administrative expense rose 270% to $10.42 million, principally reflecting higher professional fees, share-based compensation and payroll. Research and development expense increased 37% to $1.30 million.
• Total assets were $14.73 million; total liabilities were $1.38 million, including $0.30 million of operating lease liabilities. The balance sheet reports no borrowings. Current assets were $14.22 million and current liabilities $1.32 million.
• Financing cash flow was $16.95 million, mainly from the May 2026 registered direct offering; investing cash inflow of $2.50 million was primarily short-term investment maturities. Capital expenditures were nil.
• The company reported no income tax provision. No revenue or gross margin is available to assess commercial performance.

Material changes and financing

• Net loss more than tripled year over year, while operating cash use increased by $4.58 million.
• On May 22, 2026, the company sold 985,222 shares at $20.30 per share, receiving approximately $18.62 million net. Shares outstanding were 495,884,376 at June 30, 2026.
• A $500 million at-the-market offering facility was established in March 2026; no shares had been sold under it as of the report date. Further sales could materially dilute shareholders.
• Share-based compensation expense was $3.23 million, versus $0.24 million in FY2025. The company also repurchased vested options; disclosures report differing repurchase amounts in different sections, which investors should reconcile.

Outlook, risks and unusual items

• Management said cash on hand should fund operations and obligations for at least 12 months from issuance of the audited statements. It expects continuing research spending and operating losses; no quantified revenue, earnings or trial-timing guidance was provided.
• The standardized TCM formula remains under development. The company says 28 participants completed three-month treatment in its second Hong Kong efficacy trial and reports improvements on assessment scores, but the study is described as uncontrolled and relies substantially on parent/caregiver reports. The filing also calls the trial ongoing, leaving its current status unclear.
• No regulatory approval applications have been filed, and the company reports no granted patents or pending patent applications. Hong Kong product registration, manufacturing authorization, safety and quality testing, and commercialization capabilities remain necessary.
• Management believes the company was a passive foreign investment company (PFIC) for FY2026, potentially creating adverse U.S. tax consequences for U.S. holders.
• The DOJ is investigating trading in the company’s shares and requested records concerning trading and corporate matters. The company is cooperating, expects significant related legal costs, cannot predict the outcome, and has not accrued a loss. A separate shareholder class action filed in April 2026 was voluntarily dismissed and closed in September 2026.
• Share-price volatility was extreme and, management says, not explained by material changes in operating results. The company cites possible short-squeeze and trading effects. It also depends heavily on its CEO and the TCM Practitioner, who is the CEO’s father; the practitioner is central to formula research.
• Management identified three material weaknesses in financial reporting controls: insufficient U.S. GAAP/SEC reporting expertise and formal procedures, no internal audit function, and inadequate segregation of duties. Management and the auditor concluded controls were ineffective; the auditor issued an adverse opinion on internal control, while giving an unqualified opinion on the financial statements.
• AI, blockchain and tokenized-data initiatives are conceptual plans, not established operating programs. The company also disclosed that it has not purchased digital assets, though management may consider a digital-asset treasury policy.

Key facts investors should verify

• Current status, protocol, independent oversight and complete results of the second efficacy trial, including how parent-reported endpoints and medication discontinuation were handled.
• Regulatory pathway, required safety and quality testing, and whether any product or manufacturing applications have since been submitted; verify the status of patent filings.
• Cash runway against the $7.70 million FY2026 operating cash outflow, and management’s assumptions behind its 12-month liquidity assessment.
• Reconciliation of option repurchases, related cash payments and share-based compensation disclosures; assess potential dilution from outstanding options and the ATM facility.
• Developments in the DOJ investigation, potential costs or sanctions, and any subsequent legal proceedings.
• Remediation progress on material weaknesses and any later auditor assessment of internal controls.
• CEO’s reported 88.3% beneficial ownership, related-party arrangements, and the company’s possible PFIC status and investor reporting implications.